Gross margin pressure from rising API costs
Geopolitical tensions may increase API prices, impacting gross margins. Management noted indirect impact but expects to manage within 80% gross margin band.
medium · analyst_questionCorona Remedies Ltd — Q4 FY26
Corona Remedies delivered a strong FY26, with revenue of ₹1,403 Cr (+17.3% YoY) and PAT of ₹199 Cr (+33.4% YoY), exceeding guided ranges.
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Integration and margin dilution from Wokadin acquisition
Wokadin acquisition may cause ~400bps gross margin correction in first year due to NLEM portfolio. Management expects 25% revenue growth but margin recovery uncertain.
medium · analyst_questionExecution risk in new divisions and biosimilars
New infertility and multispecialty divisions, plus biosimilar launches, require ramp-up time. PCPM for new hires takes 3+ years to mature.
low · management_commentary